natgillin/translations-raw huggingface dataset:
Ekkymose, petekkier, abnorme hvide blodlegemer, reduceret tromboplastin, abnorme erytrocytter, dehydrering, forøget gonadotropt luteiniserende hormon, vægttab, forøget alkalisk fosfatase, forøget kreatininfosfokinase, forøget lipase, hyperkalcæmi, migræne, perifer neuritis, paræstesi, hypertoni, konfusion, angst, emotionel labilitet, somnolens, nedsat libido, nervøsitet, natteblindhed, nystagmus, lakrimeringsforstyrrelser, tinnitus, smagsforvrængning, thoraxsmerter, arytmi, perifer vaskulær lidelse, universelt ødem, hæmoptyse, dyspnø, øget hosten, sinuitis, pharyngitis, dysfagi, sårdannelse i munden, oral moniliasis, stomatitis, dyspepsi, tørst, abnorm afføring, opstød, vesikobulløst udslæt, makulopapulært udslæt, kramper i benene, hæmaturi, influenzasyndrom, bækkensmerter og kropslugt.
Ecchymosis, petechia, abnormal white blood cells, thromboplastin decreased, abnormal erythrocytes, dehydration, increased gonadotrophic luteinizing hormone, weight loss, increased alkaline phosphatase, increased creatinine phosphokinase, lipase increased, hypercalcaemia, migraine, peripheral neuritis, paraesthesia, hypertonia, confusion, anxiety, emotional lability, somnolence, decreased libido, nervousness, night blindness, nystagmus, lacrimation disorder, tinnitus, taste perversion, chest pain, arrhythmia, peripheral vascular disorder, generalized oedema, haemoptysis, dyspnoea, increased cough, sinusitis, pharyngitis, dysphagia, mouth ulceration, oral moniliasis, stomatitis, dyspepsia, thirst, abnormal stools, eructation, vesicobullous rash, maculopapular rash, leg cramps, haematuria, flu syndrome, pelvic pain, and body odour.
Hvis der opstår synsbesvær, mens du tager dette lægemiddel, kan det være nødvendigt, at du får lavet øjenundersøgelser periodisk.
Periodic eye exams may be needed if you experience visual difficulties while taking this medicine.
• dexamethason (anvendes mod betændelsestilstande),
• dexamethasone (used for inflammatory conditions),
Hjælpestoffer, som behandleren skal være opmærksom på: sorbitol
Excipient(s) with known effect: sorbitol
Der blev også rapporteret om enkeltstående observationer af følgende: Knoglemarvsdepression, nedsat protrombin, nedsat gonadotropt luteiniserende hormon, forøget amylase, hyponatriæmi, hypokaliæmi, hyperurikæmi, hypokolesterolæmi, hypolipæmi, hypomagnesæmi, unormal gang, stupor, circumoral paræstesi, abnorm tankegang, øjensmerter, hypovolæmi, subduralt hæmatom, kronisk hjerteinsufficiens, palpitation, epistaxis, vaskulær anomali, vaskulær lidelse, bleghed, pneumoni, respiratorisk lidelse, lungelidelse, pleural lidelse, cholecystitis, leverskade, gulsot, kolestatisk gulsot, melæna, opkastning, laryngisme, tenesmus, rhinitis, øget appetit, gingivitis,
Single observations of the following were also reported: bone marrow depression, decreased prothrombin, decreased gonadotrophic luteinizing hormone, increased amylase, hyponatraemia, hypokalaemia, hyperuricaemia, hypocholesterolaemia, hypolipaemia, hypomagnesaemia, abnormal gait, stupor, circumoral paraesthesia, abnormal thinking, eye pain, hypovolaemia, subdural haematoma, congestive heart failure, palpitation, epistaxis, vascular anomaly, vascular disorder, pallor, pneumonia, respiratory disorder, lung disorder, pleural disorder, cholecystitis, liver damage, jaundice, cholestatic jaundice, melaena, vomiting, laryngismus, tenesmus, rhinitis, increased appetite, gingivitis, herpes zoster, psoriasis, furunculosis, contact dermatitis, seborrhoea, lichenoid dermatitis, arthritis, joint disorder, urinary retention, impaired urination, polyuria, nocturia, impotence, urine abnormality, breast enlargement, carcinoma, photosensitivity reaction, face oedema, malaise, viral infection, enlarged abdomen.
Fertile kvinder skal anvende passende, præventive forholdsregler, mens bexaroten anvendes.
Women of childbearing potential must use adequate birth-control measures when bexarotene is used.
En negativ virkning i form af cataract dannelse ved langtidsbehandling med bexaroten er ikke udelukket for menneskers vedkommende.
An adverse effect of long-term bexarotene treatment on cataract formation in humans has not been excluded.
Nyligt observerede bivirkninger
Newly observed adverse reactions
Thyroideasygdom Hypertyroidisme
Hyperthyroidism
Offwhite kapsel påtrykt navnet “Targretin” og indeholdende en flydende opløsning.
Off-white capsule, containing a liquid suspension and imprinted with “Targretin”.
Antal 75 mg Targretinkapsler
Number of 75 mg Targretin capsules
Sjældne bivirkninger med dødeligt udfald er akut betændelsestilstand af bugspytkirtlen, hovedblødning og leversvigt.
Rare fatal side effects are acute inflammation of the pancreas, bleeding in the head, and liver failure.
Kapselskal: gelatine sorbitol-special-glycerinblanding (glycerin, sorbitol, sorbitolanhydrider (1,4-sorbitan), mannitol og vand) titandioxid (E171) trykfarve (SDA 35A alkohol (ethanol og ætylacetat), propylenglykol (E1520), sort jernoxid (E172), polyvinylacetatphthalat, renset vand, isopropylalkohol, macrogol 400, ammoniumhydroxid 28%)
Capsule shell: gelatin sorbitol special-glycerin blend (glycerin, sorbitol, sorbitol anhydrides (1,4-sorbitan), mannitol and water) titanium dioxide (E171) printing ink (SDA 35A alcohol (ethanol & ethyl acetate), propylene glycol (E1520), iron oxide black (E172), polyvinyl acetate phthalate, purified water, isopropyl alcohol, macrogol 400, ammonium hydroxide 28%)
Fasteniveauet af blodlipider (triglycerider og kolesterol) bør fastslås, før bexaroten-terapi indledes og med ugentlige intervaller, indtil blodlipidernes reaktion over for bexaroten er fastslået.
Fasting blood lipid determinations (triglycerides and cholesterol) should be performed before bexarotene therapy is initiated and at weekly intervals until the lipid response to bexarotene is established, which usually occurs within two to four weeks, and then at intervals no less than monthly thereafter.
Opkastning Diarré Kvalme Anoreksi Abnorme leverfunktionsprøver Cheilitis Mundtørhed Obstipation
Vomiting Diarrhoea Nausea Anorexia Liver Function Tests Abnormal Cheilitis Dry Mouth Constipation Flatulence
Bexaroten kan muligvis inducere metaboliseringsenzymer og derved teoretisk mindske østro-progestative præventionsmidlers virkning (se pkt.
Bexarotene can potentially induce metabolic enzymes and thereby theoretically reduce the efficacy of oestroprogestative contraceptives (see section 4.5).
BILAG 1
ANNEX I
Rygsmerte, hudinfektion, feber, parasitinfektion, abnorme laboratorieprøver, lidelse i slimhinder, svulst.
Back pain, skin infection, fever, parasitic infection, abnormal laboratory test, disorder of mucous membrane, tumour.
En kapsel indeholder 75 mg bexaroten.
One capsule contains 75 mg of bexarotene.
Hårforandringer, herpes simplex, negleforandringer, pustuløst udslæt, serøs dræning, hudmisfarvning.
Changes in hair, herpes simplex, nail disorder, pustular rash, serous drainage, skin discoloration.
Pankreatitis Leversvigt Gastrointestinale gener
Pancreatitis Hepatic Failure Gastrointestinal Disorder
Kvalme, diarré, tør mund, tørre læber, appetittab, forstoppelse, overdreven tarmvind, abnorm leverfunktion, opkastning.
Nausea, diarrhoea, dry mouth, dry lips, loss of appetite, constipation, excess gas, abnormal liver function tests, vomiting.
Denne vurdering er på baggrund af metabolitternes in vitro-binding og deres retinoid-receptorprofil samt på den relative mængde af de enkelte metabolitter i plasma.
Based on the in vitro binding and the retinoid receptor activation profile of the metabolites, and on the relative amounts of individual metabolites in plasma, the metabolites have little impact on the pharmacological profile of retinoid receptor activation by bexarotene.
På grund af dets hovedsageligt RXR-bindende aktivitet er det mindre sandsynligt, at bexaroten forårsager mukokutan toksicitet, negle- og hårtoksiciteter, artralgi og myalgi.
Owing to its primarily RXR-binding activity, bexarotene is less likely to cause mucocutaneous, nail, and hair toxicities; arthralgia; and myalgia; which are frequently reported with retinoic acid receptor (RAR) -binding agents.
Kapslens skal består af gelatine, sorbitol-special-glycerinblanding (glycerin, sorbitol, sorbitolanhydrider, (1,4-sorbitan), mannitol og vand), titandioxid (E171) og trykfarve (SDA 35A alkohol (ethanol og ætylacetat), propylenglykol (E1520), sort jernoxid (E172), polyvinylacetatphthalat, renset vand, isopropylalkohol, macrogol 400, ammoniumhydroxid 28%).
The capsule shell consists of gelatin, sorbitol special-glycerine blend (glycerin, sorbitol, sorbitol anhydrides (1,4-sorbitan), mannitol and water), titanium dioxide (E171) and printing ink (SDA 35A alcohol (ethanol & ethyl acetate), propylene glycol (E1520), iron oxide black (E172), polyvinyl acetate phthalate, purified water, isopropyl alcohol, macrogol 400, ammonium hydroxide 28%).
Kliniske undersøgelser har meldt om akut pankreatitis i forbindelse med forhøjede serumtriglycerider.
Acute pancreatitis associated with elevations of fasting serum triglycerides has been reported in clinical studies.
Brug af anden medicin sammen med Targretin Fortæl altid lægen, hvis du tager anden medicin eller har gjort det for nylig eller planlægger at tage lægemidler som
Tell your doctor if you are taking, have recently taken or might take any other medicines, such as
udløbsdato
EXPIRY DATE
Nervesystem et
Nervous system disorders
Bivirkninger konstateret med øget hyppighed, når bexaroten blev indgivet i en dosis på >300 mg/m2/dag til non-CTCL-cancerpatienter (sammenlignet med indgivelse til CTCLpatienter i en dosis på 300 mg/m2/dag)
adverse reactions noted with increased frequency when bexarotene was administered at a dose of >300 mg/m2/day (compared to administration to CTCL patients at 300 mg/m2/day) in non-CTCL cancer patients.
Hver kapsel indeholder 75 mg bexaroten.
Each capsule contains 75 mg of bexarotene.
Abnormt syn, uskarpt syn, betændelse af øjenlågene, stær, betændelsestilstand af øjets hvide del, hornhindelæsion, ørelidelse, defekt synsfelt.
Abnormal vision, blurred vision, inflammation of the eye lids, cataract, inflammation of the white part of the eye, lesion of the cornea of the eye, ear disorder, defect in field of vision.
Før behandlingen påbegyndes, vil der blive taget blodprøver for at vurdere din lever- og skjoldbruskkirtelfunktion samt for at måle antallet af røde og hvide blodceller.
Blood tests to evaluate the function of your liver and thyroid gland and to monitor your red blood cell and white blood cell counts will be obtained before therapy is started and will be monitored during therapy.
Ved systemisk eksponering, som er klinisk opnåelig for mennesker, optrådte der hos rotter og hunde behandlet med bexaroten irreversibel cataract i hindens bagerste område.
Irreversible cataracts involving the posterior area of the lens occurred in rats and dogs treated with bexarotene at systemic exposures that are achievable clinically in humans.
Almene symptomer og reaktioner på administratio nsstedet
General disorders and administration site conditions
Hvis påkrævet kan doseringen nedsættes (fra bexaroten 300 mg/m2 /dag til 200 mg/m2 /dag, og til 100 mg/m2 /dag, i fald det er nødvendigt), eller terapien kan afbrydes.
If fasting triglycerides are elevated or become elevated during treatment, institution of antilipaemic therapy is recommended, and if necessary, dose reductions (from 300 mg/m2/day of bexarotene to 200 mg/m2/day, and if necessary to 100 mg/m2/day) or treatment discontinuation.
Ikke almindelig (kan forekomme hos op til 1 ud af 100 behandlede): Blodforstyrrelser, eosinofili, leukocytose, lymfocytose, purpura (spontan blødning i hud og slimhinder), forhøjet eller nedsat antal blodplader.
Blood disorders, eosinophilia, leukocytosis, lymphocytosis, purpura, elevated and decreased numbers of blood platelets.
Leukopeni
Leucopenia
Hudsår Alopeci Hudhypertrofi Hudknude Akne Perspiration Tør hud Hudlidelse
Skin Ulcer Alopecia Skin Hypertrophy Skin Nodule Acne Sweating Dry Skin Skin Disorder
Ukontrolleret hypertriglyceridæmi
Uncontrolled hypertriglyceridaemia.
Blandt disse blev det senere fastslået, at leversvigt ikke var forbundet med bexaroten.
Of these, liver failure, subsequently determined to be not related to bexarotene, was the only one to occur in a CTCL patient.
- Aktivt stof: Hver Targretin-kapsel indeholder 75 mg af det virksomme stof, bexaroten.
Each Targretin capsule contains 75 mg of the active substance bexarotene.
Fødedygtige kvinder uden effektiv prævention Tidligere tilfælde af pankreatitis
Women of child-bearing potential without effective birth-control measures.
Eksfoliativ dermatitis Pruritus Udslæt
Exfoliative Dermatitis Pruritus Rash
Muskelsvaghed.
Muscle weakness.
Serøs drænage Herpes simplex Pustuløst udslæt Hudmisfarvning Hårlidelse Neglelidelse
Serous Drainage Herpes Simplex Pustular Rash Skin Discoloration Hair Disorder Nail Disorder
Sådan skal du tage Targretin
How to take Targretin
TARGRETIN 75 mg kapsler, bløde Bexaroten
TARGRETIN 75 mg soft capsules Bexarotene
Hæmoglobinniveauets udgangsværdi bør fastslås og måles ugentligt i den første måned og derefter månedligt.
Determination of haemoglobin should be obtained at baseline, weekly during the first month and then monthly thereafter.
Hududtørring, hudlidelse, hårtab, sårdannelse på huden, filipenser, fortykkelse af huden, hudknude, øget svedning.
Dry skin, skin disorder, loss of hair, skin ulcer, acne, skin thickening, skin nodule, increased sweating.
Der er i kliniske undersøgelser indtaget bexaroten i doser på op til 1000 mg/m 2/dag uden akut,
Doses up to 1000 mg/m 2/day of bexarotene have been administered in clinical studies with no acute toxic effects.
Det skal du vide, før du begynder at tage Targretin Sådan skal du tage Targretin Bivirkninger
What Targretin is and what it is used for What you need to know before you take Targretin How to take Targretin
Abnormaliteter ved leverfunktionstestning (LFT) Der foreligger meldinger om LFT-forhøjelse i forbindelse med anvendelsen af bexaroten.
LFT elevations associated with the use of bexarotene have been reported.
Ledsmerter, knoglesmerter, muskelømhed.
Joint aches, bone pain, muscle aches.
Targretin 75 mg bløde kapsler.
Targretin 75 mg soft capsules
Arthritis urica Bilirubinæmi Forhøjet blod urea nitrogen Reduceret HDLkolesterol
Gout Bilirubinemia BUN Increased High Density Lipoprotein Decreased
Kliniske undersøgelser har meldt om anæmi i forbindelse med bexaroten-terapi.
Anaemia associated with bexarotene therapy has been reported in clinical studies.
Butyleret hydroxyanisol kan forårsage irritation af slimhinderne.
Butylated hydroxyanisole may cause irritation to the mucous membranes, therefore the capsules must be swallowed intact and not chewed.
Kliniske undersøgelser har fastslået, at hyperlipidæmi er en virkning forbundet med bexaroten.
Hyperlipidaemia has been identified as an effect associated with the use of bexarotene in clinical studies.
På baggrund af bexarotens oxidative metabolisme gennem cytokrom P450 3A4 (CYP3A4), kan samtidig indgivelse af andre CYP3A4-substrater så som ketoconazol,
On the basis of the oxidative metabolism of bexarotene by cytochrome P450 3A4 (CYP3A4), coadministration with other CYP3A4 substrates such as ketoconazole, itraconazole, protease inhibitors, clarithromycin and erythromycin may theoretically lead to an increase in plasma bexarotene concentrations.
Kliniske undersøgelser har meldt om leukopeni i forbindelse med bexaroten-terapi.
Leucopenia associated with bexarotene therapy has been reported in clinical studies.
Mave-tarmforstyrrelse, leversvigt, betændelsestilstand af bugspytkirtlen.
Gastrointestinal disorder, liver failure, inflammation of the pancreas.
Samtidig indtagelse af gemfibrozil medførte dog en væsentlig forøgelse i plasmakoncentrationen af bexaroten.
However, concomitant administration of gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene and therefore, concomitant administration of gemfibrozil with bexarotene is not recommended (see section 4.5).
Perifert ødem
Ear disorder
Ændringer ved thyroideafunktionstestning
Thyroid function test alterations
Myastaeni
Myalgia
Hypotyroidisme
Hypothyroidism
Overaktiv skjoldbruskkirtel.
Overactive thyroid.
Knoglesmerter Artralgi Myalgi
Musculoskeletal and connective tissue disorders
Kontakt lægen, skadestuen eller apoteket, hvis du har taget flere Tagretin-kapsler, end der står her, eller flere end lægen har foreskrevet.
If you take more Targretin than you should If you have taken more than the prescribed dose of Targretin, you must contact your doctor.
Kontakt lægen, inden du tager dette lægemiddel, hvis lægen har fortalt dig, at du ikke tåler visse sukkerarter.
If you have an intolerance to some sugars, speak to your doctor before taking this medicinal product.
Blødning Hypertension Ødem Vasodilatation Åreknuder
Haemorrhage Hypertension Oedema Vasodilatation Varicose Vein
Skjoldbruskkirtelforstyrrelse.
Thyroid disorder.
200 (2 x 100) tabletter (multipakke)
200 (2 x 100) tablets (multipack)
Den potentielle risiko hos mennesker er ukendt.
The potential risk for humans is unknown.
Halveringstiden er 8-12 timer.
Elimination half-life is 8-12 hours.
Mindre end 1% af dosis udskilles uændret i urinen.
Less than 1% of the dose is excreted unchanged in urine.
TABEL 2
TABLE 2
Kombinationen bør derfor gives med forsigtighed, især til ældre.
Therefore, the combination should be administered with caution, especially in the elderly.
Der er også links til websites om sjældne sygdomme og hvordan de behandles.
There are also links to other websites about rare diseases and treatments.
Steady state plasmakoncentrationer nås inden for 5 dages behandling.
Steady state plasma concentrations are reached within 5 days of treatment.
Indtagelse sammen med føde (fedtrigt måltid) forsinker absorptionen omkring 1 time og øger den totale
Dosing with food (high fat meal) delays absorption by about 1 hour with an increase in total
• når der modtages ny information, der kan have indflydelse på den gældende sikkerhedsspecifikation, pharmacovigilance-plan eller på risikominimeringsaktiviteter
• When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities
Statusrapporten vil omfatte komplet dokumentation for tiltag til at opnå målet for årlig rekrutering: forventet øgning i antal er 30 patienter pr. år.
The progress report will include full documentation of efforts to achieve the target for yearly recruitment: an increased number of 30 patients/year is expected.
Spørg lægen til råds, før du tager disse to typer medicin samtidig.
Ask your doctor for advice before taking both of these medicines together.
Virkningen af celecoxib på andre lægemidler
Effects of celecoxib on other medicinal products
Hvis du bliver svimmel eller træt efter at have taget Onsenal, bør du ikke køre bil eller betjene maskiner, før du føler dig normal igen.
If you feel dizzy or tired after taking Onsenal, do not drive or use machinery until you are feeling normal again.
Kliniske aspekter:
Clinical aspects
Forsøgspopulationen omfattede 58 patienter med en tidligere subtotal eller total kolektomi og 25 patienter med en intakt colon.
The study population included 58 patients with a prior subtotal or total colectomy and 25 patients with an intact colon.
• Kendt overfølsomhed over for sulfonamider.
• Known hypersensitivity to sulphonamides.
Du kan finde yderligere information om Onsenal på Det europæiske Lægemiddelagenturs (EMAs) hjemmeside http://www.ema.europa.eu/.
Detailed information on this medicine is available on the European Medicines Agency (EMA) web site: http://www.ema.europa.eu/.
Brug af Onsenal sammen med mad og drikke Du kan tage Onsenal sammen med mad eller uden for måltider.
Taking ONSENAL with food and drink You can take Onsenal with or without food.
Der er ikke foretaget undersøgelser af virkningen på evnen til at føre motorkøretøj eller betjene maskiner.
No studies on the effect on the ability to drive and use machines have been performed.
Ældre: Dosis til ældre FAP-patienter er ikke fastlagt.
Elderly: The dose for elderly FAP patients has not been established.
Onsenal indeholder:
What ONSENAL contains
Imidlertid bør passende monitorering af methotrexatrelateret toksicitet overvejes, når disse to lægemidler kombineres.
However, adequate monitoring for methotrexate-related toxicity should be considered when combining these two
Svært nedsat nyrefunktion er en kontraindikation for anvendelse.
Severe renal impairment is a contraindication to use.
• Patienter med nyreinsufficiens med estimeret kreatinclearance <30 ml/min.
• Patients with renal insufficiency with estimated creatinine clearance <30 ml/ min.
Tag altid Onsenal nøjagtigt efter lægens anvisning.
Always take Onsenal exactly as your doctor has told you.
Den maksimale anbefalede daglige dosis er 800 mg.
The maximum recommended daily dose is 800 mg.
• Aktivt peptisk ulcus eller gastrointestinal (GI) blødning.
• Active peptic ulceration or gastrointestinal (GI) bleeding.
Onsenal er godkendt under ”særlige omstændigheder”.
This medicine has been authorised under “exceptional circumstances”.
Der er ingen klinisk erfaring med overdosering i kliniske forsøg.
There is no clinical experience of overdose in clinical trials.
Hyppigheden af disse bivirkninger er svær at bestemme, men anses generelt for at være meget sjældne (forekommer hos mindre end 1 person ud af 10.000):
The frequencies of these reactions are difficult to determine but are generally considered to be very rare (affecting less than 1 person in every 10,000)
Celecoxibs plasmakoncentration er øget ca. 100% hos ældre kvinder (65 år).
The plasma concentration of celecoxib is approximately 100% increased in elderly women (>65 years).
Du må ikke tage Onsenal, hvis du er gravid, eller hvis der er mulighed, at du bliver gravid.
You must not take Onsenal if you are pregnant or if it is possible that you become pregnant.
Den kliniske betydning af disse in vitro-fund er ikke kendt.
The clinical significance of this in vitro finding is unknown.
Cyclooxygenase er ansvarlig for dannelsen af prostaglandiner.
Cyclooxygenase is responsible for generation of prostaglandins.
Da ikke alle bivirkninger bliver rapporteret til indehaveren af markedsføringstilladelsen og dermed ikke er inkluderet i sikkerhedsdatabasen, kan hyppigheden af disse bivirkninger ikke bestemmes på pålidelig måde.
Because not all adverse drug reactions are reported to the MAH and included in the safety database, the frequencies of these reactions cannot be reliably determined.
Onsenal kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger.
Like all medicines, ONSENAL can cause side effects, although not everybody gets them.
• Pfizer Manufacturing Deutschland GmbH, Heinrich-Mack-Strasse 35, 89257 Illertissen, Tyskland
• Pfizer Manufacturing Deutschland GmbH, Heinrich-Mack-Strasse 35, 89257 Illertissen, Germany
En randomiseret dobbelt-blind placebokontrolleret undersøgelse blev udført med 83 FAP-patienter.
A randomized double-blind placebo controlled study was conducted in 83 patients with FAP.
Indehaveren af markedsføringstilladelsen vil indsende en statusrapport til CHIP-forsøget, herunder en opdatering af sikkerhedsdata, i forbindelse med den 8. årlige revurdering og vil indsende den endelige forsøgsrapport for det afsluttede forsøg, så snart denne er tilgængelig.
The MAH will submit a progress report for the CHIP trial, including an update on safety data, in the 8th annual reassessment and will submit a full study report for the completed study when available.
Der bør udvises forsigtighed, da der savnes erfaring med doser højere end 200 mg hos disse patienter.
Caution should be used as there is no experience in such patients at doses higher than 200 mg.
Familiær adenomatøs polypose (FAP) er en genetisk sygdom, som skyldes en autosomal dominant genetisk forandring af et tumorsuppressorgen, adenomatosis polyposis coli-gen (APC-gen).
Familial Adenomatous Polyposis (FAP) is a genetic disease resulting from an autosomal dominant genetic alteration of a tumor suppressor gene, the adenomatous polyposis coli (APC) gene.
Celecoxib absorberes godt og når maksimal plasmakoncentration efter ca. 2-3 timer.
Celecoxib is well absorbed reaching peak plasma concentrations after approximately 2-3 hours.